Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy

Fanghua Chen; Junming Wang; Yingcheng Wu; Qiang Gao; Shu Zhang

doi:10.3389/fonc.2022.822449

Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy

Front Oncol. 2022 Feb 3:12:822449. doi: 10.3389/fonc.2022.822449. eCollection 2022.

Authors

Fanghua Chen^{1

2}, Junming Wang², Yingcheng Wu², Qiang Gao^{1

2}, Shu Zhang^{1

2}

Affiliations

¹ Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
² Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.

Abstract

Liver cancer is the fourth leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) accounts for about 85%-90% of all primary liver malignancies. However, only 20-30% of HCC patients are eligible for curative therapy mainly due to the lack of early-detection strategies, highlighting the significance of reliable and accurate biomarkers. The integration of multi-omics became an important tool for biomarker screening and unique alterations in tumor-associated genes, transcripts, proteins, post-translational modifications and metabolites have been observed. We here summarized the novel biomarkers for HCC diagnosis based on multi-omics technology as well as the clinical significance of these potential biomarkers in the early detection of HCC.

Keywords: biomarker; clinical diagnosis; early detection; hepatocellular carcinoma; multi-omics.

Publication types

Review